BioProcess International - CEPI and Samsung Biologics Partner
webThis resource covers a biopharma industry partnership for pandemic preparedness and has minimal direct relevance to AI safety topics; it may be tangentially relevant to global catastrophic risk coordination discussions.
Metadata
Importance: 12/100news articlenews
Summary
CEPI and Samsung Biologics have formed a partnership with a $20 million initial budget to strengthen vaccine manufacturing preparedness, particularly for low- and middle-income countries. Samsung Biologics joins CEPI's Vaccine Manufacturing Facility Network as its first East Asian partner, focusing on scalable recombinant-protein vaccine manufacturing using mammalian cell-based infrastructure. The collaboration supports CEPI's 100 Days Mission to enable rapid vaccine deployment against future pandemic threats.
Key Points
- •Samsung Biologics becomes CEPI's first East Asian manufacturing partner, joining organizations from Brazil, India, Indonesia, South Africa, and Senegal in the VMFN.
- •Partnership backed by an initial $20 million budget to develop scalable recombinant-protein vaccine manufacturing processes.
- •Supports CEPI's 100 Days Mission: building infrastructure to develop and deploy vaccines within 100 days of a new pandemic threat.
- •Focus on improving vaccine access and manufacturing capacity in low- and middle-income countries (LMICs).
- •Leverages Samsung's mammalian cell-based infrastructure for rapid scaling in response to emerging viral threats.
Cited by 1 page
| Page | Type | Quality |
|---|---|---|
| Coalition for Epidemic Preparedness Innovations | Organization | 53.0 |
Cached Content Preview
HTTP 200Fetched Apr 7, 202610 KB
CEPI and Samsung partner to enhance global vaccine access Stay Updated Stay Updated Upstream Related Topics
Bioreactors
Biochemicals/Raw Materials
Cell Culture Media
Expression Platforms
Microbial Cell Culture
Perfusion Cell Culture
Recent in Upstream
See all Cell Line Development Optimizing Cell-Line Development for Antibody Derivatives: Build In Quality from the Start Optimizing Cell-Line Development for Antibody Derivatives: Build In Quality from the Start by Brian Gazaille , Séverine Fagète Mar 31, 2026 Sponsored Content eBook: Bioreactor Scale-Up — Learning from Industry Experience eBook: Bioreactor Scale-Up — Learning from Industry Experience by Brian Gazaille , Muhammad Arshad Chaudhry and 4 more Feb 25, 2026 Downstream Related Topics
Chromatography
Filtration
Separation/Purification
Viral Clearance
Recent in Downstream
See all Filtration Development of a Closed-System Approach for Downstream Processing of Large Viruses: A Case Study Using Poxvirus as a Model for Preclinical and Clinical Applications Development of a Closed-System Approach for Downstream Processing of Large Viruses: A Case Study Using Poxvirus as a Model for Preclinical and Clinical Applications by Tingting Ju , Salman Safdar and 3 more Mar 6, 2026 Sponsored Content Global HCP Profiling and Quantification by Native Digestion and LC-MS Analysis Global HCP Profiling and Quantification by Native Digestion and LC-MS Analysis by Johanna Barnhill , Timothy Licknack and 3 more Mar 5, 2026 Manufacturing Related Topics
Biosimilars
Continuous Bioprocessing
Facility Design/Engineering
Formulation
Single Use
Fill/Finish
Information Technology
Process Monitoring and Controls
Supply Chain
Validation
CMC Forums
Recent in Manufacturing
See all Facility Design/Engineering Coatings in Cleanroom Design: Empowering Safe and Sterile Environments for Biopharmaceutical Manufacturing Coatings in Cleanroom Design: Empowering Safe and Sterile Environments for Biopharmaceutical Manufacturing by Sharon L. Lee Mar 27, 2026 Facility Design/Engineering From Formulation to Facility: Driving Risk-Assessment Excellence Across Products and Projects From Formulation to Facility: Driving Risk-Assessment Excellence Across Products and Projects by Archa Vermani , Sakthi SSA and 1 more Mar 23, 2026 Analytical Related Topics
QA/QC
Cell Line Development
PAT
Product Characterization
Bioanalytical Methods
Process Development
Assays
Laboratory Equipment
Recent in Analytical
See all Cell Line Development Optimizing Cell-Line Development for Antibody Derivatives: Build In Quality from the Start Optimizing Cell-Line Development for Antibody Derivatives: Build In Quality from the Start by Brian Gazaille , Séverine Fagète Mar 31, 2026 BioProcess Insider Excalipoint secures $68.7m to advance T-Cell engager platforms Excalipoint secures $68.7m to advance T-Cell engager platforms by Nnenna Ohaka Mar 18, 2026 2 Min Read Business Related Topics
... (truncated, 10 KB total)Resource ID:
4fdf27f4683a1dae | Stable ID: sid_Nb3IE2yWg9